OncoMatch/Clinical Trials/NCT06742515
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
Is NCT06742515 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Blinatumomab plus Reduced-dose Chemotherapy for precursor b-cell acute lymphoblastic leukemia.
Treatment: Blinatumomab plus Reduced-dose Chemotherapy — Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults. Traditional treatment regimens mainly include chemotherapy and hematopoietic stem cell transplantation. In the past decade, with the application of molecular targeted drugs and immunotherapy, the survival of B-ALL patients has significantly improved. In this study，we propose a treatment approach that combines Blinatumomab and Reduced-dose Chemotherapy in B-ALL adults. Our study aims to answer the safety and efficacy of this treatment regimen, and further improve the survival for those participants.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: BCR fusion
be negative for Philadelphia chromosome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Kidney function
serum creatinine ≤ 1.5 ULN
Liver function
Serum total bilirubin ≤ 1.5 ULN; ALT or AST ≤ 2.5 ULN
Cardiac function
LVEF ≥ 45%
Serum total bilirubin > 1.5 ULN (upper limit of normal); ALT or AST > 2.5 ULN; serum creatinine > 1.5 ULN; Cardiac ultrasound LVEF < 45%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify